San Diego, CA (PRWEB) February 08, 2013
The pharmaceutical world has been racing for the cure for cancer for decades with what most experts agree is limited success. The current drugs are either so toxic and damaging to the body that many patients have to weigh the benefits of their use or the drugs are only designed to treat specific types of cancers and often only specific “strains” of specific cancers.
There is now an emerging world class sprinter in the race to create the “Super Drug” – Kalos Therapeutics. The “Super Drug” in the cancer world refers to a drug that may be used to treat multiple types of cancer and their various strains while avoiding the additional trauma often caused by chemotherapy, radiation and many of the current cancer drugs.
Kalos Therapeutics is an emerging biomedical company with the exclusive patent to develop the ANP (Atrial Natriuretic Peptide) family of peptides as a new mechanism for the treatment of cancer.
Kalos is pioneering an approach to cancer treatment by developing peptides made primarily in the heart, as a cytostatic therapeutic for treating aggressive cancers by engaging known pathway receptors more efficiently without the side effects associated with chemotherapeutic or small molecule compounds.
George Colberg, the CEO of Kalos Therapeutics, has amassed a who’s who dream team representing the best and brightest of the cancer and bio-tech worlds. More importantly is the fact that the team has the ability to think differently about what is the most effective way to treat cancer. It is that difference in thinking that appears to be producing a game changing cancer therapy.
“Kalos has successfully leveraged the natural antiproliferative activity of the Atrial Natriuretic Peptide (ANP) family of peptides in our pat
Copyright©2012 Vocus, Inc.
All rights reserved